Analytical Chemistry Shared Resource (ACSR)

分析化学共享资源：摘要 分析化学共享资源(ACSR)增强了分析化学大学的能力和生产力 亚利桑那州癌症中心(UACC)的研究人员通过为 支持基础、转化和临床研究的生物分析化学分析。ACSR提供 从研究设计咨询和方法开发到样品存储的全面服务， 准备、化验和数据分析。ACSR成立于2001年，提供多种生物分析方法。 以及开发和验证新方法的能力。使用尖端仪器，ACSR 生产高灵敏度的癌症治疗药物、防腐剂、生物活性食品的定量测量 各种生物中的成分、营养物质、致癌物、无机元素和内源代谢物 样本，以及非靶向代谢组学和脂类组学方面的定性研究。ACSR还 支持药代动力学(PK)研究设计、数据分析和数据解释。小慧联合执导 (Sherry)Chow博士和Justin Snider博士，ACSR由两名具有深厚专业知识的工作人员提供支持 外源性和内源性小分子的定量分析和非靶向代谢组学分析。 ACSR利用各种机制来评估程序需求，并严重依赖 科学咨询委员会和成员调查，确定服务和能力发展的优先顺序。一个 扩大生物分析化验方案的储存库，其中许多方案可以很容易地应用于新项目， 以符合成本效益的方式支持广泛的研究项目，以满足用户的时间表。ACSR是 能够在2020年招聘斯奈德后进行非靶向代谢组学/血脂组学分析 最近获得了使用最先进的仪器进行此类分析的机会。ACSR提供的服务包括 对评估新的癌症治疗药物的系统生物利用度和组织分布至关重要 预防干预.测量全身和靶组织致癌物暴露的程度.测量 体液和组织中内源性代谢物作为替代癌症风险和/或终点生物标记物 基于人群的临床和转化性研究；以及评估代谢变化以定义 癌症发生的潜在机制，并开发新的治疗策略。在2020财年，ACSR有 支持33名调查人员(70%为UACC成员)。在2020财年8243小时的仪器使用时间中，86%是 为UACC成员准备的。这项工作资助了23个资助项目和3个由研究人员发起的临床项目 癌症治疗和预防干预试验(IITs)。ACSR提供生物分析化学和/或 在临床前药物开发中为九种新药提供集成的PK支持。自2016年以来，ACSR服务已经 支持37份成员研究出版物和61份赠款申请。

ANALYTICAL CHEMISTRY SHARED RESOURCE: ABSTRACT The Analytical Chemistry Shared Resource (ACSR) enhances the capabilities and productivity of University of Arizona Cancer Center (UACC) investigators by providing a state-of-the-art centralized resource for bioanalytical chemistry assays to support basic, translational, and clinical research. ACSR provides comprehensive services from study design consultation and method development to sample storage, preparation, assay, and data analysis. Established in 2001, ACSR offers a wide variety of bioanalytical assays along with the capabilities to develop and validate new methods. Using cutting-edge instrumentation, ACSR produces highly sensitive quantitative measurements of cancer therapeutics, preventive agents, bioactive food components, nutrients, carcinogens, inorganic elements, and endogenous metabolites in various biological specimens, as well as qualitative studies in untargeted metabolomics and lipidomics profiling. ACSR also supports pharmacokinetic (PK) study design, data analysis, and data interpretation. Co-Directed by Hsiao-Hui (Sherry) Chow, PhD, and Justin Snider, PhD, ACSR is supported by two staff members with deep expertise in quantitative analysis of exogenous and endogenous small molecules and untargeted metabolomics analysis. ACSR utilizes various mechanisms to assess programmatic needs and relies heavily on input from the Scientific Advisory Committee and member surveys to prioritize development of services and capabilities. An expanding repository of bioanalytical assay protocols, many of which can be readily applied to new projects, support a broad spectrum of research projects in a cost-effective manner to meet user timelines. ACSR is capable of performing untargeted metabolomics/lipidomics analyses with the recruitment of Snider in 2020 and recently acquired access to state-of-the art instrumentation for such analyses. Services provided by ACSR are essential for assessing the systemic bioavailability and tissue distribution of novel cancer therapeutics and preventive interventions; measuring the extent of systemic and target tissue carcinogen exposure; measuring endogenous metabolites in biofluids and tissues as surrogate cancer-risk and/or end-point biomarkers in population-based, clinical, and translational research; and assessing metabolic changes to define the mechanisms underlying carcinogenesis and develop new treatment strategies. During CY20, ACSR has supported 33 investigators (70% UACC Members). Of the 8,243 hours of instrument usage in CY20, 86% were for UACC Members. This work supported projects from 23 funded grants and three investigator-initiated clinical trials (IITs) on cancer therapeutics and preventive interventions. ACSR provided bioanalytical chemistry and/or integrated PK support for nine novel agents in preclinical drug development. Since 2016, ACSR services have supported 37 publications from Member research and the submission of 61 grant applications.